Evidence map›Paper›PMID 24400222›Full record

ReviewLiver cancer2013

Clinical trials in hepatocellular carcinoma: an update.

Ying-Chun Shen, Zhong-Zhe Lin, Chih-Hung Hsu, Chiun Hsu, Yu-Yun Shao, Ann-Lii Cheng

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Liver cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Exosomal microRNAs in hepatocellular carcinoma.Cancer cell international · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ying-Chun ShenNational Center of Excellence for Clinical Trial and Research, Taiwan (ROC) ; Department of Oncology, National Taiwan University Hospital, Taiwan (ROC).
Zhong-Zhe LinNational Center of Excellence for Clinical Trial and Research, Taiwan (ROC) ; Department of Oncology, National Taiwan University Hospital, Taiwan (ROC) ; Department of Internal Medicine, National Taiwan University Hospital, Taiwan (ROC).
Chih-Hung HsuNational Center of Excellence for Clinical Trial and Research, Taiwan (ROC) ; Department of Oncology, National Taiwan University Hospital, Taiwan (ROC) ; Department of Internal Medicine, National Taiwan University Hospital, Taiwan (ROC) ; Graduate Institute of Oncology, School of Medicine, National Taiwan University, Taiwan (ROC).
Chiun HsuNational Center of Excellence for Clinical Trial and Research, Taiwan (ROC) ; Department of Oncology, National Taiwan University Hospital, Taiwan (ROC) ; Department of Internal Medicine, National Taiwan University Hospital, Taiwan (ROC) ; Graduate Institute of Oncology, School of Medicine, National Taiwan University, Taiwan (ROC).
Yu-Yun ShaoDepartment of Oncology, National Taiwan University Hospital, Taiwan (ROC) ; Graduate Institute of Oncology, School of Medicine, National Taiwan University, Taiwan (ROC).
Ann-Lii ChengDepartment of Oncology, National Taiwan University Hospital, Taiwan (ROC) ; Department of Internal Medicine, National Taiwan University Hospital, Taiwan (ROC) ; Graduate Institute of Oncology, School of Medicine, National Taiwan University, Taiwan (ROC).
National Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The success of sorafenib has spurred an explosive increase of clinical trials testing novel molecular targets and other agents in the treatment of hepatocellular carcinoma (HCC). The paradigm of the studies has been characterized by three noticeable changes. First, the molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways for advanced HCC treatment. Agents targeting EGFR, FGFR, PI3K/Akt/mTOR, TGF-β, c-Met, MEK, IGF signaling, and histone deacetylase have been actively explored. Second, the target indication has shifted from advanced stage to early or intermediate stages of disease. The feasibility of combining locoregional therapies and targeted agents, and the use of novel agents after curative treatments are currently under active investigation. Finally, the therapeutic strategy has shifted from monotherapy to combination targeted therapy. We aim to provide a comprehensive overview of newly disclosed and ongoing clinical trials for the treatment of HCC.

Indexed as

Clinical trialHepatocellular carcinomaMolecular targeted therapy

Identifiers

PMID24400222
PMCPMC3881316
OpenAlexW1976195505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.